⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10980109 | 0.84 | — | — | |
| SCHEMBL57385 | 0.68 | — | — | |
| SCHEMBL4646997 | 0.67 | HTT (0.34) | — | |
| SCHEMBL3174098 | 0.63 | — | — | |
| SCHEMBL27748770 | 0.62 | KDM4E (0.31) | — | |
| SCHEMBL260818 | 0.62 | TDP1 (0.37) | — | |
| SCHEMBL31050548 | 0.62 | KDM4E (0.31) | — | |
| SCHEMBL16674088 | 0.61 | CA12 (0.32) | — | |
| SCHEMBL10922807 | 0.60 | — | — | |
| SCHEMBL29095245 | 0.60 | ALDH1A1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | claimed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-115210567-A | Methods of assessing efficacy of MALT1 inhibitors using NF-KB translocation assays | 詹森药业有限公司 | 2022-10-18 | — | — | CN | claimed |
| EP-4062175-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| EP-4061966-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-09-28 | — | — | EP | claimed |
| CN-114981453-A | NF-KB regulated gene expression assay for assessing efficacy of MALT1 inhibitors | 詹森药业有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220175760-A1 | PHARMACEUTICAL FORMULATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-09 | — | — | US | claimed |
| EP-3927324-A1 | PHARMACEUTICAL FORMULATIONS | Janssen Pharmaceutica NV (BE) | 2021-12-29 | — | — | EP | claimed |
| CN-113473971-A | Pharmaceutical formulations | 詹森药业有限公司 | 2021-10-01 | — | — | CN | claimed |
| WO-2021099609-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | claimed |
| WO-2021099612-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | WO | claimed |
| US-20210155990-A1 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| US-20210156865-A1 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-27 | — | — | US | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |